Background/Aims: Bortezomib (BTZ) is largely used as a chemotherapeutic agent for the treatment of cancer. However, one of the significant limiting complications of BTZ is painful peripheral neuropathy during BTZ therapy. Drugs preventing and/or treating the painful symptoms induced by BTZ are lacking since the underlying mechanisms leading to neuropathic pain remain largely unclear. The purposes of this study were to examine 1) the effects of blocking mammalian target of rapamycin (mTOR) on mechanical pain and cold hypersensitivity evoked by BTZ and 2) the underlying mechanisms responsible for the role of mTOR in regulating BTZ-induced neuropathic pain. Methods: Behavioral test was performed to determine mechanical pain and cold sensitivity in a rat model. Western blot analysis and ELISA were used to examine expression of mTOR and phosphatidylinositide 3-kinase (p-PI3K) signals, and the levels of substance P and calcitonin gene-related peptide (CGRP). Results: Systemic injection of BTZ significantly increased mechanical pain and cold sensitivity as compared with control animals (P<0.05 vs. control rats). The expression of p-mTOR, mTORmediated phosphorylation of p70 ribosomal S6 protein kinase 1 (p-S6K1), 4E-binding protein 4 (p-4E-BP1) as well as p-PI3K was amplified in the dorsal horn of spinal cord of BTZ rats as compared with control rats. Blocking mTOR by intrathecal infusion of rapamycin attenuated mechanical pain and cold hypersensitivity. Blocking PI3K signal also attenuated activities of mTOR, which was accompanied with decreasing neuropathic pain. Inhibition of either mTOR or PI3K blunted enhancement of the spinal substance P and CGRP in BTZ rats. Conclusions: The data for the first time revealed specific signaling pathways leading to BTZ-induced peripheral neuropathic pain, including the activation of mTOR and PI3K. Inhibition of these signal pathways alleviates pain. Targeting one or more of these signaling molecules may present new opportunities for treatment and management of peripheral painful neuropathy observed during chemotherapeutic application of BTZ.
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Introduction Bortezomib (BTZ), a reversible inhibitor of the proteasome complex, is used as a chemotherapeutic agent for the treatment of cancer such as multiple myeloma [1, 2] . However, the prior studies have demonstrated that dose-limiting painful peripheral neuropathy is one of the significant adverse events observed during BTZ therapy [3] . Generally, treatment options for these abnormal sensations have been restricted, partly due to a poor understanding of the underlying mechanisms leading to neuropathic pain induced by BTZ. Drugs preventing and/or treating the painful symptoms evoked by BTZ therapy are lacking. Therefore, it is significant to determine molecular mediators of BTZ-induced painful neuropathy to make therapeutic strategies and have management of chemotherapeutic in patients with multiple myeloma.
Mammalian target of rapamycin (mTOR) is a serine threonine protein kinase. There are two distinct mTOR forms of protein complexes, mTOR complex 1 (mTORC1) and mTORC2. In general, mTORC1 is composed of raptor, mLST8 and mTOR, and is known to gate translation of most proteins by phosphorylation of specific downstream effectors including, p70 ribosomal S6 protein kinase (p70 S6Ks) and 4E-BPs [4] .
Activation of mTOR, in particular, mTORC1 that is more sensitive to rapamycin, leads to promotion of the phosphorylation of downstream effectors, such as p70 S6K1 and this further governs mRNA translation [4] . The mTORC1 is well known for its critical roles in the regulation of protein synthesis and growth and evidence supports the notion that mTOR plays a role in modulating long-term neuronal plasticity [5, 6] . Particularly, mTOR, S6K1 and 4E-BP1 are presented in the spinal cord dorsal horn and contribute to transmission and modulation of pain [6] [7] [8] . i.e., intrathecal administration of rapamycin, an inhibitor of mTOR, produces antinociception in models of inflammation [8] [9] [10] . Local perfusion of rapamycin into the spinal cord attenuates formalin-induced neuronal hyperexcitability in the dorsal horn_ENREF_6 [11] . Note that rapamycin attenuates pain response and this is accompanied with downregulated mTOR, S6K1 and 4E-BP1 [12] . These findings indicate that mTOR and its downstream signals are activated under persistent pain conditions and contribute to the development of spinal pain sensitization.
The superficial dorsal horn is the first synaptic site from peripheral afferent nerves to the central nervous system [13, 14] and plays an important role in modulating pain [15, 16] . Especially, the superficial dorsal horn at the lumbar levels (i.e., L5 to L6) is the first synaptic site receiving pain inputs from the hind paw. Thus, in this study we determined the role played by mTOR at this level of lumbar superficial dorsal horn in regulating mechanical hyperalgesia and cold hypersensitivity in rats with systemic administration of BTZ. We hypothesized that BTZ upregulates the protein expression of mTOR signal pathways in the superficial dorsal horn, resulting in mechanical pain and cold hypersensitivity. Moreover, blocking spinal mTOR by intrathecal injection of rapamycin attenuates the amplified neuropathic pain response evoked by BTZ. We also hypothesized that BTZ amplifies expression of phosphatidylinositide 3-kinase (PI3K), an upstream signal of mTOR [4] . We speculated that blocking spinal PI3K would attenuate activities of mTOR pathway thereby leading to a reduction in neuropathic pain.
Moreover, the releases of neurotransmitters such as substance P and calcitonin generelated peptide (CGRP) [17] [18] [19] , within the dorsal horn play a key role in regulating pain responses [16] . Numerous neurotransmitters and related receptors in the dorsal horn have been targets to understanding of the underlying mechanisms responsible for pain [15, 16] . Accordingly, we further hypothesized that blocking mTOR and PI3K pathways attenuates the amplified levels of substance P and CGRP in the superficial dorsal horn of BTZ rats. 
Materials and Methods

Animal model of neuropathic pain
Intrathecal catheter for administration of drugs
One end of polyethylene-10 tubing was inserted intrathecally through an incision in the cisternal membrane and advanced 7-9 cm caudal until the tip of the catheter was positioned at the lumbar spinal level (L5 to L6). The other end of the intrathecal tubing was sutured to the musculature and skin at the incision site and externalized to the back of the rat. Animals were allowed to recover and then returned to the ani mal care facility where they were housed indi vidually. Five days were allowed before the experiments were performed.
Behavioral test
To quantify the mechanical sensitivity of the hindpaw, rats were placed in individual plastic boxes and allowed to acclimate for > 30 min. Mechanical paw withdrawal threshold (PWT) of rat hindpaw in response to the stimulation of von Frey filaments was determined. A series of calibrated von Frey filaments (ranging from 0.5 to 18.0 g) were applied perpendicularly to the plantar surface of the hindpaw with a sufficient force to bend the filaments for 60s or until paw withdrew. In the presence of a response, the filament of next lower force was applied. In the absence of a response, the filament of next greater force was applied. To avoid injury during tests, the cutoff strength of the von Frey filament was 18 g. The tactile stimulus producing a 50% likelihood of withdrawal was determined using the "up-down" method [20] . Each trial was repeated 2 times at ~ 2 min intervals. The mean value was used as the force produced a withdrawal response.
Thermal Place Preference System (Coulburn Instruments) was used to perform the thermal place preference test in order to assess a cold avoidance behavior. Two connecting metal plates were surrounded by a plastic enclosure. The first plate was kept at neutral temperature (25ºC) and the second plate was kept at cold temperature (12ºC). The test was performed in darkness and each session lasted 3 minutes. During the session, the rats were left free to explore both plates. The time spent on the cold plate during the entire session was recorded using an infrared camera connected to a computer to determine cold avoidance behavior. To better control behavior test, the rats were repeatedly placed on the apparatus with both plates held at room temperature (25ºC) during 3 minutes 2 days before the beginning of the experiment. Note that rats spent an equal amount of time on each plate under these conditions, suggesting that animals showed no place preference. To avoid learning or any place preference unrelated to cold, the temperature of the plates was inverted between two consecutive sessions. Two trials were made and data were averaged. Note that all behavioral tests were performed in a blind fashion.
Experimental protocol
Following collection of baseline data, a Hamilton microsyringe (250µL) was connected to the intrathecal tubing to deliver 100 μl of dimethyl sulfoxide (DMSO) as vehicle control, antagonists to mTOR (rapamycin, 10µg; Selleck Chem) and inhibitor of PI3K (LY294002, 10µM; Sigma-Aldrich). The volume of infused rapamycin and LY294002 was 100 μl. An infusion pump was used to deliver vehicle and drugs and the pump was set to constantly over a period of 60 min. Note that a prior study [12] using the same approach to intrathecally infuse rapamycin (1, 5 and 10µg) and LY294002 (1, 5 and 10µM). It was shown that 10µg of rapamycin and 10µM of LY294002 were effective to attenuate mechanical and thermal hyperalgesia. We selected those doses accordingly in our current study.
Sixty minutes after intrathecal infusion, mechanical and cold sensitiv ity of the hindpaws were again determined. Thus, six groups were included in this study as: saline rats + vehicle infusion (n=10); BTZ rats + vehicle infusion (n=15); saline rats + rapamycin (n=12); BTZ rats + rapamycin (n=16); saline rats+ LY294002 (n=8); and BTZ rats + LY294002 (n=12).
In a subset of experiments, in order to examine the effects of blocking mTOR and PI3K on substance P and CGRP vehicle (n=12), rapamycin (10µg, n=15) and LY294002 (10µM, n=15) were intrathecally given using an infusion pump, respectively. The pump was set to constantly deliver vehicle or the drugs over a period of 60 min. At the end of infusion, rats were euthanized by sodium pentobarbital (120 mg/kg, i.p.) and the superficial dorsal horn tissues (L4-L6) were obtained under an anatomical microscope for Western Blot and ELISA experiments. Western blot analysis Total protein of the superficial dorsal horn tissues was extracted by homogenizing dorsal horn sample in ice-cold immunoprecipitation assay buffer. The lysates were centrifuged and the supernatants were collected for measurements of protein concentrations. After being denatured by heating at 95°C for 5 min in buffer, the supernatant samples containing 20 μg of protein were loaded onto 4-20% Mini-PROTEAN TGX gels and electrically transferred to a polyvinylidene fluoride membrane. The membrane was blocked in 5% nonfat milk in 0.1% Tween-TBS buffer and was incubated overnight with respective primary antibody, including: rabbit anti-p-mTOR /p-S6K1/p-4E-BP1 antibodies (1:200); rabbit anti-mTOR/S6K1/4E-BP1 antibodies (1:200); rabbit anti-p-PI3K p85 (1:250). Next, the membranes were washed and incubated with an alkaline phosphatase conjugated anti-rabbit secondary antibody (1:1000). All these primary antibodies were purchased from the Abcam Co. and/or Cayman Chem Co; and goat anti-rabbit secondary antibody was purchased from Santa Cruz Biotech. The immunoreactive proteins were detected by enhanced chemiluminescence. The bands recognized by the primary antibody were visualized by exposure of the membrane onto an x-ray film. The membrane was stripped and incubated with anti-β-actin abtibody to show equal loading of the protein. Then, the film was scanned and the optical density of all bands was analyzed using the Scion Image software (NIH, USA), and values for densities of immunoreactive bands/β-actin band densities from the same lane were examined. Each of the values was then normalized to a control sample.
ELISA measurements
To examine the levels of substance P and CGRP in the superficial dorsal horn of the spinal cord, ELISA methods were employed. Substance P was measured using substance P ELISA kit following the manufacturer's instructions (Abcam Co., Cambridge, MA). Briefly, the diluted tissue supernatant (100 μl) was placed in a 96-well goat anti-mouse IgG-coated plate and incubated for 2 hours. After incubation, the plate was washed using the provided washing buffer, and the color was developed by adding PNPP (200 μl) substrate after 45 min and determined by an ELISA plate reader with a wavelength of 575 nm. The amount of substance P was calculated by using a substance P standard curve. In the similar way, the CGRP content of the samples (100 μl supernatant) was determined using a commercial CGRP ELISA kit (Cayman Chemical Co.). Briefly, the diluted samples were placed in a 96-well plate incubated with pre-coated anti-rat IgG antibody overnight, washed and developed, and quantified [21] .
Statistical analysis
All data were analyzed using two-way repeated-measures analysis of variance since the effects of preand post-infusion were compared among six treatment groups. Values were presented as means ± standard deviation of mean. For all analyses, differences were considered significant at P < 0.05. All statistical analyses were performed by using SPSS for Windows version 13.0 (SPSS Inc., Chicago, USA).
Results
Effects of blocking mTOR and PI3K on mechanical and cold sensitivity
After we obtained all the baseline data of mechanical and cold sensitivity, control vehicle, rapamycin and LY294002 were intrathecally infused. Fig. 1 (top panel) showed that BTZ decreased PWT in rats with vehicle infusion (P <0.05 vs. saline control rats; n=15) compared with saline control rats (n=10). As rapamycin (n =16) and LY294002 (n=12) were infused, a decrease in PWT evoked by BTZ was blunted as compared with PWT in BTZ rat with vehicle infusion (P <0.05, vehicle vs. rapamycin/ LY294002 in BTZ rats). Note that there was a smaller increase of PWT observed in saline control rats after infusion either rapamycin (n=12) or LY294002 (n=8), suggesting that blocking mTOR and PI3K had less effects on mechanical sensitivity in rats under healthy conditions. Fig. 1 (bottom panels) further showed that BTZ decreased % time spent on the cold plate. As rapamycin and LY294002 were intrathecally infused, the shortened time spent on the cold plate evoked by BTZ was largely recovered. Similarly, a smaller increase of % time spent on the cold plate observed in saline control rats after infusion either rapamycin or Fig. 2A showed the protein expression of p-mTOR, p-S6K1 and p-4E-BP1 as well as mTOR, S6K1 and 4E-BP1 in saline control rats and BTZ rats. BTZ significantly increased the protein levels of p-mTOR and mTOR-mediated p-S6K1 and p-4E-BP1 in the superficial dorsal horn as compared with control rats. Optical density for p-mTOR, p-S6K1 and p-4E-BP1was 1.06±0.16; 1.05±0.16; 1.03±0.15 in control rats, and 1.78±0.26; 1.67±0.25; 1.63±0.25 in BTZ rats (P < 0.05 vs. control rats, n=6-10 in each group). Note that total protein of mTOR, S6K1 and 4E-BP1 levels was not significantly increased in BTZ rats. Furthermore, Fig. 2B demonstrated that the ratio of p-mTOR, p-S6K1 and p-4E-BP1 levels vs. total protein of mTOR, S6K1 and 4E-BP1 levels was significantly increased in BTZ rats.
Expression of mTOR signal pathway
In addition, Fig. 3A showed that expression of PI3K was upregulated in BTZ rats as compared with control rats (n=6 in each group). We further examined the effects of blocking PI3K on expression of p-mTOR and p-S6K1. Fig. 3B demonstrated that the protein expression of p-mTOR and p-S6K1 was significantly increased in BTZ rats (n=6-10) as compared with saline control rats (n=6-10). When LY294002 was infused into the spinal cord of BTZ rat, the and p-4E-BP1 in the dorsal horn of the spinal cord were upregulated in BTZ rats. *P <0.05 vs. control rats (n=6-10 in each group). There were insignificant differences in total protein expression of mTOR, S6K1 and 4E-BP1 in control rats and BTZ rats (P > 0.05. n=6-10 in each group). B, The ratio of p-mTOR, p-S6K1 and p-4E-BP1 levels vs. total protein of mTOR, S6K1 and 4E-BP1 levels was significantly increased in BTZ rats. *P <0.05 vs. control rats (n=6-10 in each group).
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry amplified activities of p-mTOR and p-S6K1 evoked by BTZ were significantly attenuated (n=6-10 in each group). Nonetheless, total protein of mTOR and S6K1 levels was not significantly altered by LY294002 in BTZ rats. Fig. 3C demonstrated that the ratio of p-mTOR and p-S6K1 levels vs. total protein of mTOR and S6K1 levels was significantly increased in BTZ rats and this was inhibited after infusion of LY294002.
Levels of substance P and CGRP
In additional experiments, we examined the effects of BTZ on the levels of substance P and CGRP in the superficial dorsal horn of the spinal cord. Fig. 4 showed that substance P and CGRP were significantly increased in BTZ rats with vehicle infusion (n=12) as compared with control rats (n=10). Furthermore, blocking individual mTOR and PI3K signaling pathways by intrathecal infusion of rapamycin and LY294002 (n=15 in each group) significantly attenuated amplifications in substance P and CGRP evoked by BTZ. It is noted that LY294002 had a greater inhibitory effect on substance P and CGRP than rapamycin did.
Discussion
In this report, we observed that BTZ upregulated mTOR and its downstream signals in the dorsal horn of rats. Inhibition Fig. 4 . Effects of blocking mTOR and PI3K pathways on the levels of substance P and CGRP. BTZ significantly increased substance P and CGRP as compared with controls, and blocking mTOR and PI3K by rapamycin and LY294002 significantly attenuated the enhancement in substance P and CGRP evoked by BTZ. Note that LY294002 had a greater inhibitory effect on substance P and CGRP than rapamycin did. *P<0.05, indicated BTZ rats with vehicle infusion (n=12) vs. control rats (n =10) and BTZ rats with rapamycin (n=15) and LY294002 (n=15) infusion. # P<0.05, indicated BTZ rats with rapamycin vs. BTZ rats with LY294002. p-mTOR and p-S6K1 was amplified in the dorsal horn of BTZ rats with vehicle treatment as compared with saline control rats. Blocking PI3K signal pathway by intrathecal infusion of LY294002 attenuated increases in p-mTOR and p-S6K1 in BTZ rats. *P <0.05 vs. control animals and BTZ animals infused with LY294002 (n =6-10 in each group). C, The ratio of p-mTOR and p-S6K1 levels vs. total protein of mTOR and S6K1 levels was significantly increased in BTZ rats. This was attenuated by infusion of LY294002. *P <0.05 vs. control rats and BTZ animals infused with LY294002 (n=6-10 in each group).
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry of mTOR signal by intrathecal infusion of rapamycin alleviated mechanical pain and cold hypersensitivity. Inhibition of PI3K further attenuated mTOR expression and neuropathic pain.
We consistently observed development of mechanical hyperalgesia and cold hypersensitivity in BTZ rats. Results of the current study also demonstrated that the expression of p-mTOR, mTOR-p-S6K1, p-4E-BP1 and p-PI3K pathway were upregulated in BTZ rats as compared with control rats. Blocking mTOR by intrathecal infusion of rapamycin attenuated mechanical hyperalgesia and largely restored shortened time spent on the cold plate evoked by BTZ. Blocking PI3K signal attenuated expression of mTOR in BTZ rats and also decreased mechanical and cold hypersensitivity. Moreover, enhanced spinal substance P and CGRP evoked by BTZ were blunted after inhibition of either mTOR or PI3K.
The PI3K/Akt pathway is an intracellular signaling pathway in regulating the cell cycle. This important mechanism is directly related to cellular quiescence, proliferation, and longevity. PI3K can phosphorylate and activate Akt in the plasma membrane [22] . The Akt leads to several downstream effects which alter transcription of p70 ribosomal S6K1 or 4E-BP1 and activating cAMP response element-binding protein (CREB) and inhibition of p27 etc [4, 5, 22, 23] . Our present study demonstrated that blocking PI3K attenuated p-mTOR and p-S6K1 expression, and that intrathecal infusion of PI3K inhibitor attenuated hyperalgesia and restored shortened time spent on the cold plate observed in BTZ rats. This suggests that PI3K is necessary to play a regulatory role in mediating the effects of mTOR on BTZ-evoked mechanical pain and cold hypersensitivity responses.
It is well known that stimulation of nociceptive receptors in the sensory nerves leads to the releases of substance P and CGRP from the nerve terminal of dorsal root ganglions into the superficial dorsal horn [18, 24] . Numerous receptors present on the presynaptic site of the nerve terminals and contribute to the releases of substance P and CGRP in regulating inflammatory pain [16] . It is assumed that PI3K-mTOR pathway can indirectly affect these receptors such as transient receptor potential vanilloid 1 (TRPV1) and thereby decrease the levels of substance P and CGRP [10] . Another source of substance P and CGRP is likely originated from the dorsal horn interneurons [25, 26] . PI3K-mTOR signal pathway is likely to present in these interneurons containing two neuropeptides. Thus, blocking PI3K-mTOR can decrease the levels of those two neuropeptides. Nevertheless, in our current study, the levels of substance P and CGRP, as two important neurotransmitters engaged in pain, were significantly increased in the superficial dorsal horn of BTZ rats. Moreover, the increased substance P and CGRP were significantly attenuated after respective injection of rapamycin and LY294002. Thus, our data suggest that amplified expression of spinal mTOR and its downstream pathways S6K1 or 4E-BP1 are engaged in BTZ-induced mechanical hyperalgesia and cold hypersensitivity likely via the releases of substance P and CGRP.
Notably, we observed that LY294002 had a greater effect on substance P and CGRP than rapamycin did, indicating the role played by PI3K as a upstream pathway in regulating hypersensitive responses observed in BTZ rats via mTOR signals. This suggests that mTOR is not only downstream pathway of PI3K. Nevertheless, to the best of our knowledge there is lacking of evidence specifically showing the role played by mTOR and PI3K in regulating the releases of spinal substance P and CGRP in a neuropathic pain model induced by BTZ. Results of the present report suggest that substance P and CGRP regulated by mTOR and PI3K at the spinal level contribute to mechanical pain and cold hypersensitivity in BTZinduced neuropathy.
In conclusion, in BTZ rats, spinal p-mTOR and mTOR-mediated p-S6K1 and p-4E-BP1 are upregulated, resulting in mechanical and cold hypersensitivity. Intrathecal administration of rapamycin has analgesic effects on BTZ-induced neuropathic pain. Also, blocking PI3K blunts the amplified expression of p-mTOR and thereby alleviates BTZ-evoked neuropathic pain. Nonetheless, our data for the first time reveal specific signal pathways leading to mechanical pain and cold hypersensitivity evoked by BTZ, including the activation of PI3K and mTOR downstream pathways, and releases of substance P and CGRP. Our data provide a base for the mechanisms responsible for BTZ-induced peripheral painful neuropathy. or more of these signaling molecular mediators involved in activation of PI3K-mTOR at the spinal levels may present new opportunities for treatment and management of pain often observed in cancer patients during chemotherapeutic application of BTZ.
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